Consequently, POSTN spatial density emerges as a dual biomarker for both prognostication and rational therapeutic stratification, guiding combinations of anti‐angiogenic agents with immune checkpoint blockade to overcome microenvironment‐mediated resistance, particularly in the context of rising MASLD‐driven HCC incidence.[45, 46]. This evidence concerns the gene POSTN and hepatocellular carcinoma.